Human medicines European public assessment report (EPAR): Hirobriz Breezhaler, indacaterol, Date of authorisation: 30/11/2009, Revision: 21, Status: Withdrawn

Submitted by Anonymous (not verified) on 30 October 2026 - 14:32

Human medicines European public assessment report (EPAR): Hirobriz Breezhaler, indacaterol, Date of authorisation: 30/11/2009, Revision: 21, Status: Withdrawn

Orphan designation: (2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amNide Treatment of microscopic polyangiitis (avacopan), 19/11/2014 Withdrawn

Submitted by Anonymous (not verified) on 30 October 2026 - 14:31

Orphan designation: (2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amNide Treatment of microscopic polyangiitis (avacopan), 19/11/2014 Withdrawn

Human medicines European public assessment report (EPAR): Tavneos, avacopan, Date of authorisation: 11/01/2022, Revision: 9, Status: Revoked

Submitted by Anonymous (not verified) on 30 October 2026 - 14:29

Human medicines European public assessment report (EPAR): Tavneos, avacopan, Date of authorisation: 11/01/2022, Revision: 9, Status: Revoked

Human medicines European public assessment report (EPAR): Tryngolza, olezarsen, Date of authorisation: 17/09/2025, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 30 October 2026 - 14:26

Human medicines European public assessment report (EPAR): Tryngolza, olezarsen, Date of authorisation: 17/09/2025, Revision: 1, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More